Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Allergy & Immunology
•
Mast Cell Disorders
•
Primary Care
How do you discuss the overlap of POTS, Ehlers-Danlos and MCAS with patients?
Related Questions
Would you use febuxostat for an African-American patient with gout and previous cardiovascular events (stroke, MI) who tested positive for HLA-B*5801?
How do you choose between delgocitinib & ruxolitinib for patients with CHE?
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
Would you consider using transdermal estrogen in a patient with “high risk” APLS patient on warfarin?
Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?
Do you still consider the use of pegloticase in someone with substantial tophaceous burden despite optimal uric acid levels?
How would you approach diagnosis of a patient with recurrent episodes of abdominal pain, severe myalgias, low grade fevers and urticaria?
How often are you performing CT screening in CVID patients to screen for ILD?
How do you manage oral ulcers as a side effect from leflunomide?
In a young patient who was vaccinated to chickenpox as a child (no previous varicella infection) should the patient receive a shingles vaccine prior to starting Rinvoq?
